BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 9273186)

  • 41. Phase II study of concurrent chemotherapy and radiotherapy for unresectable stage III non-small-cell lung cancer: long-term follow-up results. Japan Clinical Oncology Group Protocol 8902.
    Kubota K; Tamura T; Fukuoka M; Furuse K; Ikegami H; Ariyoshi Y; Kurita Y; Saijo N
    Ann Oncol; 2000 Apr; 11(4):445-50. PubMed ID: 10847464
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A phase III randomized trial of combined chemoradiotherapy versus radiotherapy alone in locally advanced non-small-cell lung cancer.
    Kim TY; Yang SH; Lee SH; Park YS; Im YH; Kang WK; Ha SH; Park CI; Heo DS; Bang YJ; Kim NK
    Am J Clin Oncol; 2002 Jun; 25(3):238-43. PubMed ID: 12040280
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cisplatin and vinorelbine followed by radiotherapy in the treatment of stage III-B non-small-cell lung cancer patients.
    Felip E; Del Campo JM; Bodi R; Vera R; Casado S; Rubio D
    Am J Clin Oncol; 1997 Aug; 20(4):404-6. PubMed ID: 9256899
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A phase II study of cisplatin and 5-fluorouracil with concurrent hyperfractionated thoracic radiation for locally advanced non-small-cell lung cancer: a preliminary report from the Okayama Lung Cancer Study Group.
    Segawa Y; Ueoka H; Kiura K; Kamei H; Tabata M; Sakae K; Hiraki Y; Kawahara S; Eguchi K; Hiraki S; Harada M
    Br J Cancer; 2000 Jan; 82(1):104-11. PubMed ID: 10638975
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Neoadjuvant radiochemotherapy in locally advanced non-small cell bronchial carcinoma. Initial results of a prospective multicenter study].
    Wagner W; von Eiff M; Klinke F; Micke O; Rübe C; Willich N
    Strahlenther Onkol; 1995 Jul; 171(7):390-7. PubMed ID: 7631260
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Concurrent high-dose thoracic irradiation plus daily low-dose cisplatin and vindesine in locally advanced unresectable stage III non-small cell lung cancer].
    Nakano K; Kumagai K; Ishida H; Kohjima N; Hiramoto T; Hada Y
    Gan To Kagaku Ryoho; 1996 Jan; 23(1):57-61. PubMed ID: 8546470
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Neoadjuvant cisplatin plus vinblastine chemotherapy in locally advanced non-small cell lung cancer.
    Johnson DH; Strupp J; Greco FA; Stewart J; Merrill W; Malcolm A; Hande KR; Hainsworth JD
    Cancer; 1991 Sep; 68(6):1216-20. PubMed ID: 1651802
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Daily low-dose cisplatin plus concurrent high-dose thoracic irradiation in locally advanced unresectable non-small-cell lung cancer: results of a phase II Southwest Oncology Group study.
    Hazuka MB; Crowley JJ; Bunn PA; O'Rourke M; Braun TJ; Livingston RB
    J Clin Oncol; 1994 Sep; 12(9):1814-20. PubMed ID: 8083705
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: preliminary results of a phase III trial in regionally advanced, unresectable non-small-cell lung cancer.
    Sause WT; Scott C; Taylor S; Johnson D; Livingston R; Komaki R; Emami B; Curran WJ; Byhardt RW; Turrisi AT
    J Natl Cancer Inst; 1995 Feb; 87(3):198-205. PubMed ID: 7707407
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Docetaxel and concurrent radiotherapy after two cycles of induction chemotherapy with cisplatin and vinorelbine in patients with locally advanced non-small-cell lung cancer. A phase II trial conducted by the Groupe Francais de Pneumo-Cancerologie (GFPC).
    Vergnenègre A; Daniel C; Léna H; Fournel P; Kleisbauer JP; Le Caer H; Letreut J; Paillotin D; Pérol M; Bouchaert E; Preux PM; Robinet G;
    Lung Cancer; 2005 Mar; 47(3):395-404. PubMed ID: 15713523
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Induction chemotherapy with cetuximab, vinorelbine-cisplatin followed by thoracic radiotherapy and concurrent cetuximab, vinorelbine-cisplatin in patients with unresectable stage III non-small cell lung cancer.
    Liu D; Zheng X; Chen J; Liu G; Xu Y; Shen Y; Xie L; Zhao W; Jiang G; Fan M
    Lung Cancer; 2015 Sep; 89(3):249-54. PubMed ID: 26118463
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cisplatin, mitomycin, and vindesine followed by intraoperative and postoperative radiotherapy for stage III non-small cell lung cancer: final results of a phase II study.
    Aristu J; Rebollo J; Martínez-Monge R; Aramendía JM; Viera JC; Azinovic I; Herreros J; Brugarolas A
    Am J Clin Oncol; 1997 Jun; 20(3):276-81. PubMed ID: 9167753
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Preoperative chemotherapy (cisplatin and fluorouracil) and radiation therapy in stage III non-small cell lung cancer. A phase 2 study of the LCSG.
    Weiden PL; Piantadosi S
    Chest; 1994 Dec; 106(6 Suppl):344S-347S. PubMed ID: 7988261
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Establishment of the standard regimen for non-small-cell lung cancer in Japan.
    Masuda N
    Oncology (Williston Park); 2001 Jan; 15(1 Suppl 1):13-8. PubMed ID: 11221016
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Induction chemoradiotherapy followed by surgery for locally advanced non-small cell lung cancer.
    Kusumoto S; Hirose T; Fukayama M; Kataoka D; Hamada K; Sugiyama T; Shirai T; Yamaoka T; Okuda K; Ohnishi T; Ohmori T; Kadokura M; Adachi M
    Oncol Rep; 2009 Nov; 22(5):1157-62. PubMed ID: 19787234
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Phase II study of twice-daily high-dose thoracic radiotherapy alternating with cisplatin and vindesine for unresectable stage III non-small-cell lung cancer: Japan Clinical Oncology Group Study 9306.
    Sekine I; Nishiwaki Y; Ogino T; Yokoyama A; Saito M; Mori K; Tsukiyama I; Tsuchiya S; Hayakawa K; Yoshimura K; Ishizuka N; Saijo N
    J Clin Oncol; 2002 Feb; 20(3):797-803. PubMed ID: 11821463
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The combination of cisplatin and vinorelbine with concurrent thoracic radiation therapy for locally advanced stage IIIA or IIIB non-small-cell lung cancer.
    Hirose T; Mizutani Y; Ohmori T; Ishida H; Hosaka T; Ando K; Shirai T; Okuda K; Ohnishi T; Horichi N; Kubota H; Adachi M
    Cancer Chemother Pharmacol; 2006 Sep; 58(3):361-7. PubMed ID: 16331494
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Concurrent platinum and docetaxel chemotherapy and external radical radiotherapy in patients with invasive transitional cell bladder carcinoma. A preliminary report of tolerance and local control.
    Varveris H; Delakas D; Anezinis P; Haldeopoulos D; Mazonakis M; Damilakis J; Metaxaris G; Chondros N; Mavromanolakis E; Daskalopoulos G; Dimitrakopoulos A; Kranidis A
    Anticancer Res; 1997; 17(6D):4771-80. PubMed ID: 9494605
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Concurrent hyperfractionated irradiation and chemotherapy for unresectable nonsmall cell lung cancer. Results of Radiation Therapy Oncology Group 90-15.
    Byhardt RW; Scott CB; Ettinger DS; Curran WJ; Doggett RL; Coughlin C; Scarantino C; Rotman M; Emami B
    Cancer; 1995 May; 75(9):2337-44. PubMed ID: 7712445
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Induction cisplatin/vinblastine and irradiation vs. irradiation in unresectable squamous cell lung cancer: failure patterns by cell type in RTOG 88-08/ECOG 4588. Radiation Therapy Oncology Group. Eastern Cooperative Oncology Group.
    Komaki R; Scott CB; Sause WT; Johnson DH; Taylor SG; Lee JS; Emami B; Byhardt RW; Curran WJ; Dar AR; Cox JD
    Int J Radiat Oncol Biol Phys; 1997 Oct; 39(3):537-44. PubMed ID: 9336129
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.